| Popis: |
Background The University of Minnesota Medical Center (UMMC) is a tertiary care facility, which has had a comprehensive antimicrobial stewardship program (ASP) for 11 years. Methods The antimicrobial stewardship team is comprised of a full-time PharmD and ID staff physicians who rotate on the service. Recommendations are placed in the electronic medical record as a progress note. Verbal recommendations may also be made. Results There was a downward trend in Hospital Acquired (HA) C. difficile diarrhea from 2007 to 2014 from 1.2 to 0.5/1,000 patient-days. Rates appear stable from 2014 to 2017 with adjustment for change to NHSN laboratory-based surveillance (Figure 1). From 2009 to 2017 a decrease was seen in VRE hospital-acquired infections (HAI) from 0.53 to 0.24/1,000 patient-days and in MRSA HAIs from 0.2 to 0.04/1,000 patient-days. Newly acquired ESBL HAIs have remained relatively stable from 2009 to 2017 at 0.09 to 0.10/1,000 patient-days. CRE HAIs are an emerging problem with increasing rates (Figure 2). Cost savings continued from year to year. The greatest cost savings was observed after initial implementation (2006–2008) in which antimicrobial doses/patient day declined by 7%, antibiotics costs declined by $7.40/patient day. In 2012, we observed our lowest antibiotic cost/pt day at $37.51. Through August 2017, we have observed a sustained average antibiotic cost per patient day of $39.45 (Figure 3). After adjusting for inflation annually, our expected costs ($70.26) compared with actual costs ($40.39 ytd 2017) demonstrate effective cost management of antimicrobial agents, with saving of ~$30.00/patient day (Figure 3). Conclusion We observed a decrease in HAIs VRE and C. difficile infections after 3 years of operation, and MRSA after 5 years. ESBL HAIs remain relatively stable and CRE are emerging HAIs of concern. Therefore, we are now focusing efforts of limiting unneeded carbapenem use. Our antibiotic costs/patient day have leveled off in the last 3 years and remained low despite rising antibiotic costs due to market inflation and drug shortages. The ASP outcomes have continued to cost justify ongoing efforts. The effects of the program and the Infection Prevention Department appear to be synergistic. Figure 1: Figure 2: Figure 3: Disclosures All authors: No reported disclosures. |
